Author: R. J. Maciunas
Publisher:
ISBN: 9783131350619
Category :
Languages : en
Pages : 220

View

Book Description

Author: Robert J. Maciunas
Publisher: Thieme
ISBN: 9781879284470
Category : Cancer invasiveness
Languages : en
Pages : 344

View

Book Description
The neurosurgical treatment of metastatic tumors involving the central nervous system is being transformed by recent advances in interactive image-guided technologies and cell-specific targeted biotherapeutics. Advanced Techniques in Central Nervous System Metastases presents the research and developments being incorporated into clinical practice. Advanced Techniques in Central Nervous System Metastases covers: The current treatment of brain metastases Metastases of primary CNS tumors Craniotomy for single and multiple cerebral metastases CNS involvement by systemic malignancy in children Cranial base surgery for invasive carcinomas Interactive image-guided techniques for the biopsy and resection of metastatic cerebral tumors Use of the free-electron laser for metastatic brain tumors Gamma knife radiosurgery Endovascular treatment Decompression and stabilization of spine metastases Plus much more! (Distributed by Thieme for the American Association of Neurological Surgeons)

Author: Rohan Ramakrishna
Publisher: Springer Nature
ISBN: 303042958X
Category : Medical
Languages : en
Pages : 725

View

Book Description
This is a multi-specialty book on the diagnosis, evaluation, and treatment of CNS metastases of the brain and spine. Written by renowned experts in their fields, the book covers essential contemporary topics in CNS metastases care. The book is divided into seven parts that begin with chapters that cover the fundamental biology of disease so that subsequent chapters on imaging, diagnosis, treatment, and palliation can be properly contextualized. This text also provides a framework for understanding the biology of radiation therapy so that radiation treatment options of the brain and spine can be more fully understood. New medications and technologies are reviewed from the perspective of maximizing efficacy and minimizing toxicity, independently and as combinatorial therapy. Central Nervous System Metastases: Diagnosis and Treatment serves as a practical reference for health care providers and trainees. It provides the comprehensive, detailed perspective required to provide holistic care to patients with metastatic disease to the brain and spine.

Author: Manmeet Ahluwalia
Publisher: Springer Nature
ISBN: 3030234177
Category : Medical
Languages : en
Pages : 421

View

Book Description
This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors.

Author: Lizza E.L Hendriks
Publisher: Frontiers Media SA
ISBN: 2889457079
Category :
Languages : en
Pages : 94

View

Book Description
Approximately 40% of lung cancer patients will develop central nervous system (CNS) metastases during the course of their disease. Most of these are brain metastases, but up to 10% will develop leptomeningeal metastases. Known risk factors for CNS metastases development are small cell lung cancer (SCLC), adenocarcinoma histology, epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) rearranged lung cancer, advanced nodal status, tumor stage and younger age. CNS metastases can have a negative impact on quality of life (QoL) and overall survival (OS). The proportion of lung cancer patients diagnosed with CNS metastases has increased over the years due to increased use of brain imaging as part of initial cancer staging, advances in imaging techniques and better systemic disease control. Post contrast gadolinium enhanced magnetic resonance imaging (gd-MRI) is preferred, however when this is contra-indicated a contrast enhanced computed tomography (CE-CT) is mentioned as an alternative option. When CNS metastases are diagnosed, local treatment options consist of radiotherapy (stereotactic or whole brain) and surgery. Local treatment can be complicated by symptomatic radiation necrosis for which no high level evidence based treatment exists. Moreover, differential diagnosis with metastasis progression is difficult. Systemic treatment options have expanded over the last years. Until recently, chemotherapy was the only treatment option with a poor penetration in the CNS. Angiogenesis inhibitors are promising in the treatment of primary CNS tumors as well as radiation necrosis but clinical trials of anti-angiogenic agents in NSCLC have largely excluded patients with CNS metastases. Furthermore, research has also focused on methods to prevent development of CNS disease, for example with prophylactic cranial irradiation. Recently, checkpoint inhibitors have become available for NSCLC patients, and tyrosine kinase inhibitors (TKIs) have improved prognosis significantly in those with a druggable driver mutation. Newer TKIs are often designed to have better CNS penetration compared to first-generation TKIs. Despite advances in treatment options CNS metastases remain a problem in lung cancer and cause morbidity and mortality. This Research Topic provides an extensive resource of articles describing advances in CNS metastases management in lung cancer patients, from prevention to diagnosis and treatment.

Author: Diane Palmieri
Publisher: Springer Science & Business Media
ISBN: 9400752911
Category : Medical
Languages : en
Pages : 234

View

Book Description
Here is a thorough survey of the biology and treatment of CNS metastasis, including natural history, risk factors, molecular biology, the blood-brain barrier, imaging, quality of life, surgery, chemotherapy, radiation and the future of targeted therapies.

Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 0

View

Book Description
Approximately 40% of lung cancer patients will develop central nervous system (CNS) metastases during the course of their disease. Most of these are brain metastases, but up to 10% will develop leptomeningeal metastases. Known risk factors for CNS metastases development are small cell lung cancer (SCLC), adenocarcinoma histology, epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) rearranged lung cancer, advanced nodal status, tumor stage and younger age. CNS metastases can have a negative impact on quality of life (QoL) and overall survival (OS). The proportion of lung cancer patients diagnosed with CNS metastases has increased over the years due to increased use of brain imaging as part of initial cancer staging, advances in imaging techniques and better systemic disease control. Post contrast gadolinium enhanced magnetic resonance imaging (gd-MRI) is preferred, however when this is contra-indicated a contrast enhanced computed tomography (CE-CT) is mentioned as an alternative option. When CNS metastases are diagnosed, local treatment options consist of radiotherapy (stereotactic or whole brain) and surgery. Local treatment can be complicated by symptomatic radiation necrosis for which no high level evidence based treatment exists. Moreover, differential diagnosis with metastasis progression is difficult. Systemic treatment options have expanded over the last years. Until recently, chemotherapy was the only treatment option with a poor penetration in the CNS. Angiogenesis inhibitors are promising in the treatment of primary CNS tumors as well as radiation necrosis but clinical trials of anti-angiogenic agents in NSCLC have largely excluded patients with CNS metastases. Furthermore, research has also focused on methods to prevent development of CNS disease, for example with prophylactic cranial irradiation. Recently, checkpoint inhibitors have become available for NSCLC patients, and tyrosine kinase inhibitors (TKIs) have improved prognosis significantly in those with a druggable driver mutation. Newer TKIs are often designed to have better CNS penetration compared to first-generation TKIs. Despite advances in treatment options CNS metastases remain a problem in lung cancer and cause morbidity and mortality. This Research Topic provides an extensive resource of articles describing advances in CNS metastases management in lung cancer patients, from prevention to diagnosis and treatment.

Author: Edjah K. Nduom
Publisher: Elsevier Health Sciences
ISBN: 0323761933
Category : Medical
Languages : en
Pages : 209

View

Book Description
This issue of Neurosurgery Clinics, guest edited by Drs. Edjah Nduom and Jeff Olson, will focus on Metastases to the Central Nervous System. This issue is one of four selected each year by our series consulting editors, Dr. Russell R. Lonser and Dr. Daniel K. Resnick. Topics discussed in this issue will include: Epidemiology of metastatic CNS disease, Initial approach to the patient with a newly diagnosed solitary brain metastasis, Initial approach to the patient with multiple newly diagnosed brain metastases, When to consider a stereotactic biopsy for brain metastases, Techniques for open surgical resection of cerebral metastases, Laser ablation for cerebral metastases, Histopathological features and laboratory markers of common brain metastases, Recurrence vs radiation necrosis – evaluation and treatment, Anti-epileptic drugs for the management of cerebral metastases, Chemotherapy for the management of cerebral metastases, Approach to the management of metastatic leptomeningeal disease, Immune therapy for CNS metastases, Novel therapeutic targets for the treatment of cerebral metastases, Skull base metastases – diagnosis and management, and more.

Author: Zbigniew Petrovich
Publisher: Springer Science & Business Media
ISBN: 9783540006275
Category : Medical
Languages : en
Pages : 664

View

Book Description
The American Cancer Society anticipates that 16,500 patients will be diagnosed with primary malignant tumors of the central nervous system in 2000, with about 200,000 individuals presenting with brain metastases. The advances in the treatment of solid tumors have contributed significantly to the major increase in metastatic cancers to the brain. Of the primary malignant tumors of the brain, more than 50% are high-grade gliomas; the incidence has been increasing among older patients over the past decade. Major developments in new technologies in the treatment of primary brain tumors as well as metastatic disease are covered in depth. Even though management is difficult, advances are being made. This book is a concerted effort to present data regarding basic science research efforts alongside their translation into clinical practice using combined, integrated multimodal programs of treatment. Progress has been made, but innovatice approaches need to be pursued.

Author: National Academies of Sciences Engineering and Medicine
Publisher:
ISBN: 9780309683494
Category :
Languages : en
Pages :

View

Book Description
Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.